ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2026 · 119 positions · Total reported value $4.97B · Top-10 concentration 45.7% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, ORBIMED ADVISORS LLC disclosed 119 equity positions with a combined reported value of $4.97B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 45.7% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were EWTX ($630.52M), ELVN ($343.91M), LLY ($309.33M). By sector, the heaviest allocations are Health Care 92.3%, Industrials 1.5%.

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 60% of names.

The largest new positions opened in Q2 2026 were HUM ($65.18M), ODTX ($56.15M), ARQT ($53.54M).

Of the 23 positions fully exited versus the prior quarter, the largest were MDXH ($285.90M), MYGN ($122.88M), PFE ($54.66M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • HUM HUMANA INC COM · $65.18M
  • ODTX ODYSSEY THERAPEUTICS INC · $56.15M
  • ARQT ARCUTIS BIOTHERAPEUTICS INC COM · $53.54M
  • XBI SPDR SERIES TRUST · $47.48M
  • WST WEST PHARMACEUTICAL SVSC INC COM · $25.35M
  • AURA AURA BIOSCIENCES INC · $23.67M
  • SYRE SPYRE THERAPEUTICS INC COM NEW · $16.53M
  • WAT WATERS CORP · $15.11M

Fully Exited (vs previous quarter)

  • MDXH MDXHEALTH SA · prev qtr: $285.90M
  • MYGN MYRIAD GENETICS INC COM · prev qtr: $122.88M
  • PFE PFIZER INC · prev qtr: $54.66M
  • DHR DANAHER CORP DEL · prev qtr: $50.40M
  • RCEL AVITA MEDICAL INC · prev qtr: $42.52M
  • ESPR ESPERION THERAPEUTICS INC NE · prev qtr: $28.96M
  • BTSG BRIGHTSPRING HEALTH SVCS INC COM · prev qtr: $21.21M
  • AMGN AMGEN INC · prev qtr: $14.04M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 92.3%
Other 6.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 15.52M $630.52M 12.68%
12.68%
Hold
2 6.78M $343.91M 6.91%
6.91%
Reduce
3 257.90K $309.33M 6.22%
6.22%
Add
4 3.43M $189.27M 3.81%
3.81%
Reduce
5 2.72M $184.47M 3.71%
3.71%
Hold
6 915.70K $171.08M 3.44%
3.44%
Add
7 2.21M $118.58M 2.38%
2.38%
Add
8 2.56M $112.43M 2.26%
2.26%
Reduce
9 7.17M $107.05M 2.15%
2.15%
Hold
10 3.03M $105.17M 2.11%
2.11%
Hold
11 583.70K $87.57M 1.76%
1.76%
Add
12 92.88K $86.17M 1.73%
1.73%
Reduce
13 663.40K $85.25M 1.71%
1.71%
Hold
14 1.81M $83.25M 1.67%
1.67%
Reduce
15 230.10K $77.04M 1.55%
1.55%
Add
16 834.90K $75.53M 1.52%
1.52%
Reduce
17 3.24M $71.86M 1.45%
1.45%
Add
18 262.00K $71.12M 1.43%
1.43%
Hold
19 972.80K $69.12M 1.39%
1.39%
Add
20 8.29M $66.39M 1.33%
1.33%
Hold
21 244.46K $65.20M 1.31%
1.31%
Add
22 164.10K $65.18M 1.31%
1.31%
New
23 1.48M $63.30M 1.27%
1.27%
Reduce
24 157.90K $62.79M 1.26%
1.26%
Reduce
25 2.11M $56.94M 1.15%
1.15%
Add
26 3.00M $56.15M 1.13%
1.13%
New
27 892.47K $53.87M 1.08%
1.08%
Reduce
28 2.04M $53.54M 1.08%
1.08%
New
29 925.00K $53.30M 1.07%
1.07%
Hold
30 4.13M $52.59M 1.06%
1.06%
Add
31 159.10K $50.09M 1.01%
1.01%
Reduce
32 2.81M $50.02M 1.00%
1.00%
Hold
33 300.00K $47.48M 0.95%
0.95%
New
34 90.70K $45.47M 0.91%
0.91%
Add
35 6.31M $43.76M 0.88%
0.88%
Hold
36 5.69M $39.40M 0.79%
0.79%
Hold
37 999.00K $37.38M 0.75%
0.75%
Hold
38 322.90K $35.85M 0.72%
0.72%
Add
39 1.54M $33.71M 0.68%
0.68%
Add
40 1.58M $33.53M 0.67%
0.67%
Add
41 15.22M $33.33M 0.67%
0.67%
Hold
42 465.35K $32.49M 0.65%
0.65%
Add
43 83.20K $30.92M 0.62%
0.62%
Add
44 5.68M $30.28M 0.61%
0.61%
Reduce
45 117.58K $28.78M 0.58%
0.58%
Reduce
46 420.60K $26.90M 0.54%
0.54%
Add
47 1.43M $26.67M 0.54%
0.54%
Reduce
48 200.00K $26.65M 0.54%
0.54%
Reduce
49 357.54K $26.15M 0.53%
0.53%
Reduce
50 70.60K $25.35M 0.51%
0.51%
New

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 60% R 60% F1 60% (modelled on 2026-Q1; 6/10 hit)

Low-confidence forecast This fund replaces about 22% of its Top-10 each quarter and backtests at F1 79% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 79% · recall 79% · F1 79% · avg rank error 1.9 · Top-10 turnover 22%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 80% 80% 80% SVA · LLY · BIIB · BSX · ISRG · EWTX · BMRN · RYZB · ELVN · MRK SVA · LLY · EWTX · BSX · ISRG · BIIB · MRK · JANX · ELVN · THC
2024-Q2 100% 100% 100% SVA · LLY · EWTX · BSX · BIIB · ISRG · MRK · JANX · ELVN · THC SVA · LLY · EWTX · BSX · ISRG · BIIB · ELVN · MRK · THC · JANX
2024-Q3 90% 90% 90% SVA · LLY · EWTX · BSX · ISRG · BIIB · ELVN · MRK · THC · JANX EWTX · SVA · LLY · BSX · ISRG · ELVN · BIIB · MRK · THC · SYK
2024-Q4 70% 70% 70% EWTX · SVA · LLY · BSX · ISRG · ELVN · BIIB · MRK · SYK · THC EWTX · SVA · BSX · LLY · ISRG · ELVN · NBIX · SYK · SRPT · ARGX
2025-Q1 80% 80% 80% EWTX · SVA · BSX · LLY · ISRG · ELVN · NBIX · SRPT · SYK · ARGX SVA · EWTX · BSX · LLY · ELVN · ISRG · SYK · ARGX · EW · UNH
2025-Q2 90% 90% 90% SVA · EWTX · BSX · LLY · ELVN · ISRG · SYK · ARGX · EW · NBIX SVA · BSX · LLY · EWTX · ELVN · ISRG · SPRY · SYK · EW · ARGX
2025-Q3 80% 80% 80% SVA · BSX · LLY · EWTX · ELVN · ISRG · SPRY · SYK · EW · ARGX EWTX · LLY · SVA · ELVN · ALNY · SYK · EW · ISRG · ARGX · SION
2025-Q4 70% 70% 70% EWTX · LLY · SVA · ELVN · ALNY · SYK · EW · ISRG · ARGX · SION EWTX · LLY · BSX · SVA · UPB · ISRG · SION · MBX · ARGX · ELVN
2026-Q1 70% 70% 70% EWTX · LLY · BSX · SVA · UPB · ISRG · SION · MBX · ELVN · ARGX EWTX · ELVN · MDXH · LLY · SVA · BSX · SION · AZN · MYGN · MBX
2026-Q2 ★ 60% 60% 60% EWTX · ELVN · MDXH · LLY · SVA · BSX · AZN · SION · MYGN · EW EWTX · ELVN · LLY · MBX · SVA · AZN · GPCR · SION · CRVS · AVBP

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did ORBIMED ADVISORS LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, ORBIMED ADVISORS LLC reported 119 equity positions worth $4.97B in aggregate; its largest disclosed positions were EWTX ($630.52M), ELVN ($343.91M), LLY ($309.33M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $4.97B of long equity holdings across 119 positions as of 2026-Q2. Top-10 holdings account for 45.7% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →